Antiviral Medication for Flu Offers Dual Benefits by Protecting Close Contacts from Infection

A recent study published in the New England Journal of Medicine highlights an exciting advancement in influenza treatment. Researchers have found that a single dose of the antiviral drug baloxavir marboxil, commercially known as Xofluza, not only shortens the duration of illness in treated patients but also significantly reduces the likelihood of transmitting the virus to household members. This discovery stems from the groundbreaking CENTERSTONE trial, which involved over 4,100 participants, including influenza-positive individuals aged 5 to 64 and their household contacts.

The study revealed that patients who received baloxavir had about a 30% lower chance of passing the infection to their family members compared to those given a placebo. The research was led by Dr. Arnold Monto from the University of Michigan, along with co-author Dr. Adam Lauring. One of the notable aspects of baloxavir is its single-dose formulation, contrasting with other antivirals that require a five-day daily regimen. This simplifies treatment and encourages wider use, potentially leading to greater public health benefits.

Dr. Monto explained that the study was designed specifically to evaluate whether antiviral treatment could curb transmission, and the results have confirmed this possibility. The findings suggest that administering baloxavir early in the course of infection could effectively reduce the spread of influenza within households and communities.

The implications of this research extend beyond human flu viruses. Laboratory studies indicate that baloxavir may also inhibit avian influenza viruses, offering hope for controlling future outbreaks of bird and possibly zoonotic flu strains.

Experts believe that increasing the use of such antiviral treatments not only benefits individual patients by shortening illness and preventing complications but also serves as a vital strategy for disease prevention by lowering transmission rates.

This discovery comes at a critical time when public health officials seek more effective measures to combat seasonal and pandemic influenza. The research underscores the importance of prompt antiviral therapy and opens new avenues for community-level influenza control strategies. For more details, consult the original study: Arnold S. Monto et al., ‘Efficacy of Baloxavir Treatment in Preventing Transmission of Influenza,’ New England Journal of Medicine, 2025. (source: https://medicalxpress.com/news/2025-04-drug-flu-additional-benefit-contacts.html).